Two-Drug attack on tough leukemia shows promise
NCT ID NCT04329325
First seen Apr 08, 2026 · Last updated Apr 21, 2026 · Updated 3 times
Summary
This study is testing whether adding a drug called blinatumomab to standard treatment improves outcomes for adults with a specific type of acute lymphoblastic leukemia (Ph+ ALL). The goal is to help patients achieve a deeper response where cancer markers are undetectable. The approach aims to control the disease while reducing the need for harsh chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Mount Sinai Hospital
New York, New York, 10029, United States
Conditions
Explore the condition pages connected to this study.